Pharma Focus Europe
ThermoFisher Scientific - Custom and Bulks

Intravacc and Primrose Bio Collaborate to Enhance Conjugate Vaccine Development

Thursday, March 28, 2024

Intravacc, a globally recognized contract development and manufacturing organization (CDMO) specializing in infectious disease and therapeutic vaccines, has announced a strategic partnership with Primrose Bio, a biotechnology company known for its advanced technologies in improving the manufacturing of next-generation therapeutics. Together, they plan to enhance the development and distribution of conjugate vaccines, providing third-party developers with a seamless solution for vaccine conjugation, manufacturing, and supply.

Dr. Jan Groen, CEO of Intravacc, expresses excitement about the collaboration: "Our partnership with Primrose Bio marks an exciting milestone. By combining our expertise with Primrose's cutting-edge technologies, we aim to revolutionize the landscape of conjugate vaccine development, ultimately benefiting millions globally."

Dr. Helge Zieler, CEO of Primrose Bio, adds: "Expanding the capabilities of our PeliCRM197® franchise through collaboration with Intravacc creates a comprehensive solution for our early-stage customers and partners engaged in vaccine conjugation development. With both entities boasting direct proficiency in preclinical, manufacturing, and clinical development, our combined knowledge addresses a crucial need within the vaccine industry."

This alliance leverages the complementary strengths of both organizations, fostering innovation and efficiency in vaccine development. Intravacc brings its extensive technical expertise, state-of-the-art facilities, and robust capabilities in antigen conjugation process development, scale-up, and GMP production of conjugate vaccines. Primrose Bio complements these assets with its ultra-pure production, supply chain, and regulatory support for the PeliCRM197® carrier protein, a critical component in conjugate vaccine formulations and the sole commercial CRM197 used in available commercial vaccines. This carrier protein is offered in various quantities and grades, catering to research and GMP applications alike. The partnership signifies a strategic alignment aimed at propelling vaccine development and accessibility for researchers and industry clients.

 

Source: globenewswire.com

magazine-slider-img
Get instant
access to our latest e-book
patheon - Mastering API production at every scaleLab Indonesia 20247th Pharma Packaging and Labelling Forum 2024Future Labs Live - 2024World Orphan Drug Congress 2024World Vaccine Congress Europe 2024Sartorius Webinar - Pave Your Weigh to Accurate Analytical ResultsEUROPEAN PHARMA OUTSOURCING SUMMIT 2024patheon - Revolutionizing PharmaWorld Vaccine Congress Europe 2024